Daxor Corporation announced new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company's BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 patients. Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.65 USD | -2.92% | -1.03% | +0.52% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.52% | 46.38M | |
+3.74% | 12.61B | |
+5.50% | 9.01B | |
-3.20% | 5.41B | |
+5.63% | 5.19B | |
+2.44% | 5.25B | |
+14.36% | 4.48B | |
+16.67% | 4.44B | |
+1.53% | 4B | |
+1.56% | 3.75B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients